LITTLE KNOWN FACTS ABOUT AGO TUMOR.

In summary, throughout the last 10 years by far the most outstanding edge is accomplished in HER2/neu-overexpressing MBC. Introduction of bevacizumab for a VEGF-directed focused remedy remains a concern on debate. A lot of the novel therapeutics to your breast cancer armamentarium resulted in prolongation of survival for patients with MBC. At this